This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Endometrial differential 3 (EDI3)	<p>Patient sample and <i>in vitro</i> studies suggest inhibiting EDI3 could help treat cancer. Researchers identified the enzyme EDI3, which cleaves glycerophosphocholine (GPC) to choline. Also, high levels of EDI3 were associated with low relapse-free survival in human patients with endometrial and ovarian cancer. In breast cancer cells, anti-EDI3 small interfering RNA increased GPC levels and decreased choline levels and cell migration compared with siRNA control. Next steps include identifying EDI3 inhibitors.</p> <p>SciBX 5(22); doi:10.1038/scibx.2012.569 Published online May 31, 2012</p>	Findings patented; licensed to an undisclosed company	<p>Stewart, J.D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online May 8, 2012; doi:10.1073/pnas.1117654109</p> <p>Contact: Jan G. Hengstler, Technical University of Dortmund, Dortmund, Germany e-mail: hengstler@ifado.de</p>